Novel Agents Generate Excitement in Advanced HCC, Cholangiocarcinoma
Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.
Related Articles
CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer
The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.
Novel BTK Inhibitor LP-168 Under Investigation in China for R/R Mantle Cell Lymphoma
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.
FDA Approves Amivantamab Plus Chemo for EGFR+ Advanced NSCLC After an EGFR Inhibitor
The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.
AR Degraders, Other Novel Agents Could Expand Armamentarium in mCRPC
Sandy Srinivas, MD, discusses the therapeutic landscape of mCRPC and the need to develop novel treatment options.
Zanubrutinib/Rituximab Induction May Be Safe and Effective in Newly Diagnosed Mantle Cell Lymphoma
The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.
Rintatolimod Plus Durvalumab Shows Early Disease Control in Late-Stage Pancreatic Cancer
Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.
Pelareorep Plus Chemo Improves OS in Endocrine-Refractory HR+/HER2– Advanced Breast Cancer
Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.
First-Line Zanubrutinib/Obinutuzumab Shows Efficacy, Safety in Older MCL
The frontline combination of obinutuzumab and zanubrutinib demonstrated efficacy and safety in older patients with mantle cell lymphoma.
Non-Hispanic Black Children Experience Inferior Post-Relapse Survival Outcomes vs Whites With Nonmetastatic Osteosarcoma
R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer
Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.